HESHAM MOHAMED to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications HESHAM MOHAMED has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.066
-
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):341-349.e1.
Score: 0.033
-
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407.
Score: 0.033